NEWS & RESOURCES
Estrigenix in the news
Estrigenix Therapeutics to Attend The Menopause Society Meeting
MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier…
Estrigenix welcomes new employees
Estrigenix Therapeutics welcomed two new employees this summer, Ms. Elaina Milkie and Dr. Dulanjali Thennakoon. Ms. Elaina Milkie graduated with B.S. from the University of Wisconsin-Milwaukee (UWM) in May 2023, double majoring in Psychology and Biological Sciences. Elaina worked part time with Estrigenix in spring 2023 while completing her degree…
Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC
Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation. The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback…
Estrigenix Therapeutics, Inc. presents at Precision Drug Discovery & Preclinical Summit 2023 in Boston
MILWAUKEE (June , 2022) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the Precision Drug Discovery & Preclinical (PDDP) Summit 2023 in Boston. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an…
Estrigenix CSO Karyn Frick Featured on “FemTech Focus” Podcast
MILWAUKEE (May 16, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, was recently featured on the podcast FemTech Focus hosted by Brittany Baretto, PhD. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Dr. Baretto regarding Estrigenix’s first-in-class therapeutics to…
Estrigenix Therapeutics’ Scientific Advisor, Dr. Pauline Maki Ph.D., Receives Health Education Visionary Award
Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is excited to announce that Dr. Pauline Maki Ph.D., a member of our Scientific Advisory Board, is receiving the Health Education Visionary Award from The Society for Women’s Health Research (SWHR) at their 2003 Annual…